NEU: Revenue up 8% and interim dividend declared, but net profit down 68% on higher R&D costsQuartr·Aug 25 at 11:49 PM
Repligen Stock And 2 Dollar Beneficiaries Gaining Attention After Fed Rate ShiftSimplywall·Jul 13 at 01:01 PMRGEN-1.19%SNDK+11.90%
The 10 most shorted ASX stocks plus the biggest risers and fallers – Week 29Market Index·Jul 13 at 03:29 AMZIP+0.72%
Neuren Pharmaceuticals (ASX:NEU) Wins CHMP Backing, Is The Upside Already Priced In?Simplywall·Jul 2 at 08:02 AM
Neurizon Therapeutics Gains Ethics Approval for NUZ-001 Oral Liquid Phase 1 StudySmall Caps·May 13 at 02:34 AM
Neuren launches Investor Hub to bolster engagement as neurological pipeline advancesTip Ranks·May 12 at 06:05 AM
Neurizon Targets Investor Visibility with NUZ-001 ALS Update at Microcap ConferenceTip Ranks·May 11 at 03:32 AM
Bell Potter Reaffirms Their Buy Rating on Neuren Pharmaceuticals Limited (NURPF)Tip Ranks·May 9 at 09:05 AM
Neuren Pharmaceuticals Outlines Procedures for Virtual Shareholder MeetingTip Ranks·Apr 24 at 03:38 AM
